A Study Into the Effect of Seprafilm in Open Total Thyroidectomy
- Conditions
- Thyroid Carcinoma
- Interventions
- Device: Seprafilm (Sanofi, USA)
- Registration Number
- NCT01865838
- Lead Sponsor
- National Cancer Centre, Singapore
- Brief Summary
The investigators intend to determine the role of Seprafilm, a popular anti-adhesive agent in minimising internal adhesion formation in the neck after thyroid surgery and therefore reduce swallowing discomfort experienced by patients after surgery.
- Detailed Description
Thyroid surgery not only constitutes one of the main pillars in the treatment of thyroid cancers, but is also employed in the management of symptomatic goitres. Occasionally, it is mandated in patients with thyrotoxicosis refractory to medical therapy. While thyroid surgery can be performed with low risks such that patients rarely have to stay beyond three days in hospital, the track record of thyroid surgery is somewhat blemished by the unfortunate side effects associated with the neck scarring after thyroid surgery. Not uncommonly, patients experience discomfort in the neck region after thyroid surgery; in the extreme of cases, patients may even complain of a lifelong pulling sensation in the neck area during eating.
The anti-adhesive properties of Seprafilm are well established in animal studies and affirmed by clinical observations in abdominal surgeries that utilize this material. Thus, Seprafilm is routinely used in instances when a surgeon foresees a need to perform abdominal surgery on the same patient in future, or during the fashioning of a temporary stoma. The safety profile of Seprafilm in thyroidectomy has also been shown by a recent study conducted by a group of clinicians in Seoul.
We postulate that the application of Seprafilm to the surgical wound towards the end of a thyroidectomy significantly reduces internal adhesion formation in the neck region. By achieving this objective, we hope to improve patients' satisfaction with thyroid surgery in terms of ease of swallowing after surgery.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 19
- Age 21-75
- Histological confirmation of differentiated thyroid cancer requiring surgery, symptomatic goiters, thyroid nodules requiring histological analysis, or thyrotoxicosis poorly controlled by medication.
- Undergoing total thyroidectomy
- Previous neck surgery
- Previous neck radiotherapy
- Patients with a known history of keloids
- Patients with a known history of motility disorders in the upper gastrointestinal tract and preexisting swallowing difficulty.
- Patients with metastatic disease; patients with disease that would require postop radiation therapy, radionuclide iodine therapy and any adjuvant therapies.
- Patients with advanced disease that would require radical or modified neck dissection
- Patients with lobe larger than 10 cm, or nodule larger than 8 cm which require extensive dissection that may confound the study
- Patients with connective tissue diseases and chronic diseases on long-term medications that may interfere with wound healings such as steroids
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Seprafilm (Sanofi, USA) Seprafilm (Sanofi, USA) Patients in this arm received Seprafilm during surgery.
- Primary Outcome Measures
Name Time Method Cricoid elevation 1 to 14 days before the surgery, postop day 14 and 3 months postop Trial candidates are to undergo videofluoroscopy to assess their swallowing and cricoid elevation is measured using ImageJ.
* First measurement is 1 to 14 days before the surgery.
* Second measurement is 14 days postop.
* Third measurement is 3 months postop.
- Secondary Outcome Measures
Name Time Method Hyoid elevation 1 to 14 days before the surgery, postop day 14 and 3 months postop Trial candidates are to undergo videofluoroscopy to assess their swallowing and hyoid elevation is measured using ImageJ.
* First measurement is 1 to 14 days before the surgery.
* Second measurement is 14 days postop.
* Third measurement is 3 months postop.Crico-hyoid distance 1 to 14 days before the surgery, postop day 14 and 3 months postop Trial candidates are to undergo videofluoroscopy to assess their swallowing and hyoid elevation is measured using ImageJ.
* 1 to 14 days before the surgery
* Second measurement is 14 days postop.
* Third measurement is 3 months postop.Videotaping measurement 1 to 14 days before the surgery, postop day 14 and 3 months postop Trial candidates are to undergo videotaping of their surgical incision site during swallowing. Maximal displacement of the incision site will be measured and recorded using ImageJ.
* First measurement is 1 to 14 days before the surgery.
* Second measurement is 14 days postop.
* Third measurement is 3 months postop.Swallowing Quality of Life questionaire 1 to 14 days before the surgery, postop day 14 and 3 months postop Trial candidates will be interviewed regarding their swallowing using the Sydney Swallowing questionnaire. Patients will be interviewed three times.
* First interview is 1 to 14 days before the surgery.
* Second interview is 14 days postop.
* Third interview is 3 months postop.
Trial Locations
- Locations (2)
National Cancer Centre Singapore
🇸🇬Singapore, Singapore
Singapore General Hospital
🇸🇬Singapore, Singapore